Sofya Tokman1, Jonathan P Singer2, Megan S Devine3, Glen P Westall4, John-David Aubert5, Michael Tamm6, Gregory I Snell4, Joyce S Lee2, Hilary J Goldberg7, Jasleen Kukreja8, Jeffrey A Golden2, Lorriana E Leard2, Christine K Garcia3, Steven R Hays2. 1. Division of Pulmonary and Critical Care Medicine, University of California, San Francisco Medical Center, San Francisco, California. Electronic address: sofya.tokman@gmail.com. 2. Division of Pulmonary and Critical Care Medicine, University of California, San Francisco Medical Center, San Francisco, California. 3. Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. 4. Division of Respiratory Medicine, Alfred Hospital, Melbourne, Australia. 5. Division of Respiratory Medicine, Lausanne University Hospital, Lausanne, Switzerland. 6. Division of Respiratory Medicine, Basel University Hospital, Basel, Switzerland. 7. Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 8. Division of Cardiothoracic Surgery, University of California, San Francisco Medical Center, San Francisco, California.
Abstract
BACKGROUND: Successful lung transplantation for patients with pulmonary fibrosis from telomerase mutations may be limited by systemic complications of telomerase dysfunction, including myelosuppression, cirrhosis, and malignancy. We describe clinical outcomes in 14 lung transplant recipients with telomerase mutations. METHODS: Subjects underwent lung transplantation between February 2005 and April 2014 at 5 transplant centers. Data were abstracted from medical records, focusing on outcomes reflecting post-transplant treatment effects likely to be complicated by telomerase mutations. RESULTS: The median age of subjects was 60.5 years (interquartile range = 52.0-62.0), 64.3% were male, and the mean post-transplant observation time was 3.2 years (SD ± 2.9). A mutation in telomerase reverse transcriptase was present in 11 subjects, a telomerase RNA component mutation was present in 2 subjects, and an uncharacterized mutation was present in 1 subject. After lung transplantation, 10 subjects were leukopenic and 5 did not tolerate lymphocyte anti-proliferative agents. Six subjects developed recurrent lower respiratory tract infections, 7 developed acute cellular rejection (A1), and 4 developed chronic lung allograft dysfunction. Eight subjects developed at least 1 episode of acute renal failure and 10 developed chronic renal insufficiency. In addition, 3 subjects developed cancer. No subjects had cirrhosis. At data censorship, 13 subjects were alive. CONCLUSIONS: The clinical course for lung transplant recipients with telomerase mutations is complicated by renal disease, leukopenia with intolerance of lymphocyte anti-proliferative agents, and recurrent lower respiratory tract infections. In contrast, cirrhosis was absent, acute cellular rejection was mild, and development of chronic lung allograft dysfunction was comparable to other lung transplant recipients. Although it poses challenges, lung transplantation may be feasible for patients with pulmonary fibrosis from telomerase mutations.
BACKGROUND: Successful lung transplantation for patients with pulmonary fibrosis from telomerase mutations may be limited by systemic complications of telomerase dysfunction, including myelosuppression, cirrhosis, and malignancy. We describe clinical outcomes in 14 lung transplant recipients with telomerase mutations. METHODS: Subjects underwent lung transplantation between February 2005 and April 2014 at 5 transplant centers. Data were abstracted from medical records, focusing on outcomes reflecting post-transplant treatment effects likely to be complicated by telomerase mutations. RESULTS: The median age of subjects was 60.5 years (interquartile range = 52.0-62.0), 64.3% were male, and the mean post-transplant observation time was 3.2 years (SD ± 2.9). A mutation in telomerase reverse transcriptase was present in 11 subjects, a telomerase RNA component mutation was present in 2 subjects, and an uncharacterized mutation was present in 1 subject. After lung transplantation, 10 subjects were leukopenic and 5 did not tolerate lymphocyte anti-proliferative agents. Six subjects developed recurrent lower respiratory tract infections, 7 developed acute cellular rejection (A1), and 4 developed chronic lung allograft dysfunction. Eight subjects developed at least 1 episode of acute renal failure and 10 developed chronic renal insufficiency. In addition, 3 subjects developed cancer. No subjects had cirrhosis. At data censorship, 13 subjects were alive. CONCLUSIONS: The clinical course for lung transplant recipients with telomerase mutations is complicated by renal disease, leukopenia with intolerance of lymphocyte anti-proliferative agents, and recurrent lower respiratory tract infections. In contrast, cirrhosis was absent, acute cellular rejection was mild, and development of chronic lung allograft dysfunction was comparable to other lung transplant recipients. Although it poses challenges, lung transplantation may be feasible for patients with pulmonary fibrosis from telomerase mutations.
Authors: Jason D Christie; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2011-10 Impact factor: 10.247
Authors: Jason D Christie; Martin Carby; Remzi Bag; Paul Corris; Marshall Hertz; David Weill Journal: J Heart Lung Transplant Date: 2005-06-04 Impact factor: 10.247
Authors: Jason D Christie; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Anne I Dipchand; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2012-10 Impact factor: 10.247
Authors: Neelam Giri; Rees Lee; Albert Faro; Charles B Huddleston; Frances V White; Blanche P Alter; Sharon A Savage Journal: BMC Blood Disord Date: 2011-06-15
Authors: Hiroki Yamaguchi; Gabriela M Baerlocher; Peter M Lansdorp; Stephen J Chanock; Olga Nunez; Elaine Sloand; Neal S Young Journal: Blood Date: 2003-04-03 Impact factor: 22.113
Authors: Daniel Hartmann; Ujala Srivastava; Michaela Thaler; Karin N Kleinhans; Gisèle N'kontchou; Annika Scheffold; Kerstin Bauer; Ramona F Kratzer; Natalia Kloos; Sarah-Fee Katz; Zhangfa Song; Yvonne Begus-Nahrmann; Alexander Kleger; Guido von Figura; Pavel Strnad; André Lechel; Cagatay Günes; Andrej Potthoff; Katja Deterding; Heiner Wedemeyer; Zhenyu Ju; Ge Song; Feng Xiao; Sonja Gillen; Hubert Schrezenmeier; Thomas Mertens; Marianne Ziol; Helmut Friess; Michael Jarek; Michael P Manns; Michel Beaugrand; K Lenhard Rudolph Journal: Hepatology Date: 2011-05 Impact factor: 17.425
Authors: Leann L Silhan; Pali D Shah; Daniel C Chambers; Laurie D Snyder; Gerdt C Riise; Christa L Wagner; Eva Hellström-Lindberg; Jonathan B Orens; Juliette F Mewton; Sonye K Danoff; Murat O Arcasoy; Mary Armanios Journal: Eur Respir J Date: 2014-05-15 Impact factor: 16.671
Authors: Chad A Newton; Julia Kozlitina; Jefferson R Lines; Vaidehi Kaza; Fernando Torres; Christine Kim Garcia Journal: J Heart Lung Transplant Date: 2017-02-04 Impact factor: 10.247
Authors: Chad A Newton; David Zhang; Justin M Oldham; Julia Kozlitina; Shwu-Fan Ma; Fernando J Martinez; Ganesh Raghu; Imre Noth; Christine Kim Garcia Journal: Am J Respir Crit Care Med Date: 2019-08-01 Impact factor: 21.405
Authors: Slavé Petrovski; Jamie L Todd; Michael T Durheim; Quanli Wang; Jason W Chien; Fran L Kelly; Courtney Frankel; Caroline M Mebane; Zhong Ren; Joshua Bridgers; Thomas J Urban; Colin D Malone; Ashley Finlen Copeland; Christie Brinkley; Andrew S Allen; Thomas O'Riordan; John G McHutchison; Scott M Palmer; David B Goldstein Journal: Am J Respir Crit Care Med Date: 2017-07-01 Impact factor: 21.405
Authors: Simone Feurstein; Ayodeji Adegunsoye; Danijela Mojsilovic; Rekha Vij; Allison H West DePersia; Padma Sheila Rajagopal; Afaf Osman; Robert H Collins; Raymond H Kim; Steven D Gore; Peter Greenberg; Lucy A Godley; Zejuan Li; Daniela Del Gaudio; Hari Prasanna Subramanian; Soma Das; Tom Walsh; Suleyman Gulsuner; Jeremy P Segal; Aliya N Husain; Sandeep Gurbuxani; Mary-Claire King; Mary E Strek; Jane E Churpek Journal: Blood Adv Date: 2020-10-13
Authors: Chad A Newton; Kiran Batra; Jose Torrealba; Julia Kozlitina; Craig S Glazer; Carlos Aravena; Keith Meyer; Ganesh Raghu; Harold R Collard; Christine Kim Garcia Journal: Eur Respir J Date: 2016-08-18 Impact factor: 16.671